Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood
about
sameAs
Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levelsAntistreptokinase platelet-activating antibodies are common and heterogeneousThe P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism.Pharmaceutical thrombosis prevention in cardiovascular disease.In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation.Single nucleotide polymorphism network: a combinatorial paradigm for risk prediction.Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.Anti-platelet therapy: ADP receptor antagonists.Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapyPharmacodynamic interplay of the P2Y(1), P2Y(12), and TxA(2) pathways in platelets: the potential of triple antiplatelet therapy with P2Y(1) receptor antagonismThe P2Y12 antagonists, 2-methylthioadenosine 5'-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels.Cangrelor: a review on its mechanism of action and clinical development.Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist.Vascular PAR-1: activity and antagonism.Update on the clinical development of cangrelor.Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease.Pharmacogenetics guided anticoagulation.Thienopyridine-associated drug-drug interactions: pharmacologic mechanisms and clinical relevance.The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.Recent advances in the pharmacogenetics of clopidogrel.CYP-mediated pharmacologic interference with optimal platelet inhibition.Platelet function profiles in patients with diabetes mellitus.Cangrelor: a review on pharmacology and clinical trial development.Novel antiplatelet agents in acute coronary syndrome.Proteomic signatures of antiplatelet drugs: new approaches to exploring drug effects.Improved Biological Activities of Isoepoxypteryxin by Biotransformation.The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays.Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor.Antithrombotic therapy for patients with STEMI undergoing primary PCI.Molecular mechanism and functional implications of thrombin-mediated tyrosine phosphorylation of PKCdelta in platelets.Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects.Effects of barbiturates on human platelet aggregation differ depending on their chemical structures.Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro.Does the use of statins compromise the effectiveness of platelet inhibition by clopidogrel?DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease.Platelet signalling networks: pathway perturbation demonstrates differential sensitivity of ADP secretion and fibrinogen binding.Recent progress and market analysis of anticoagulant drugs.
P2860
Q24816368-B66B3513-E09B-49C6-8CD5-370A6E82C560Q28196784-3313EEA5-0094-4EB0-BCDE-02706BB264E9Q34510681-C68EBE4F-00C6-44BF-9D5D-E3D27D92F2BBQ34581514-DA0E2B48-707C-46D0-A147-93DFAFA90F5AQ34721174-497849CC-CA27-45B5-8B89-361165EA7A52Q34989717-F49E4225-6F63-45B4-A573-22CA949A0D22Q35130686-BC126124-4125-4067-BC0B-7C26C8253E83Q35278165-BF564A22-7FFF-4E20-A174-FC2AA2BC89D3Q35755253-8B0D5907-9BB1-4127-8098-B4C15153CBC8Q36532804-4C984A78-3CED-406B-93FD-66FCC0633B1CQ37269228-2761FE62-5A4B-4182-945C-D6C88C55E6B8Q37611039-C75A6146-E8FA-4E9F-9301-097F9C0A7BE4Q37688144-475BE4DE-777C-45FB-AE34-FED474F4E9EAQ37763262-76BF2FA5-7133-4097-96FE-0E592C5F6D53Q37776511-E2559A9A-9E60-4C34-AA7F-44D070B3EAD4Q37797795-945A4D10-59BA-4545-B592-312B26D1ADA4Q37808224-55A0B131-47F1-45EE-871C-B43C3E380F89Q37914050-66AA794E-0BC7-4212-B2F4-DBCB54DEFA39Q37923969-5D596A79-FB0B-499E-88EA-DDAA7BEF50E3Q37972231-66CA2B7E-E0BE-4C4C-8E8A-3853794B4058Q38073672-37BD8F42-8753-40EB-B3EF-0C3042DA4FBAQ38081078-B3C5D4E6-1B71-4C97-9703-EB687CAC4C03Q38153779-6A224480-C05C-4509-86DC-709916052B2EQ38257119-79FA97B1-9297-4705-9013-021EAD00EABAQ38543311-2A133065-EC52-41F7-898F-94C077EA74BDQ38756289-E0555E33-2234-489B-AF01-B8CC41B84CADQ38790876-B795991B-85C6-44F1-BA23-1CF6608C7CADQ38974706-DF9B9626-006F-464D-9BFB-38E0C61D5107Q39147735-5AC1D54D-6E0F-453D-AD5D-9F7D8C314ED9Q42063614-501A4F9F-72A6-444F-9E3C-4564DEFA11D5Q42542451-0260F80F-8A5B-4371-A94A-320552DF4BCCQ44536229-1C9F5381-78F6-42C8-BA0F-87D9804A6D22Q44720869-7AB8DAD2-61B0-409E-AF67-591D1EEF5CBBQ44941568-8E699E62-C7E7-4B01-B8D7-F7D9DBAE482FQ46244116-27D370B8-72A6-4F50-A751-606B561B7A0DQ54546461-EFD1E3DF-ADEC-4504-8954-500B47D3996CQ55072550-37EEA83C-89F2-4DB9-B5CD-1BA8F8D61C73
P2860
Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Effects of P2Y(1) and P2Y(12) ...... agonists in human whole blood
@ast
Effects of P2Y(1) and P2Y(12) ...... agonists in human whole blood
@en
Effects of P2Y(1) and P2Y(12) ...... agonists in human whole blood
@nl
type
label
Effects of P2Y(1) and P2Y(12) ...... agonists in human whole blood
@ast
Effects of P2Y(1) and P2Y(12) ...... agonists in human whole blood
@en
Effects of P2Y(1) and P2Y(12) ...... agonists in human whole blood
@nl
prefLabel
Effects of P2Y(1) and P2Y(12) ...... agonists in human whole blood
@ast
Effects of P2Y(1) and P2Y(12) ...... agonists in human whole blood
@en
Effects of P2Y(1) and P2Y(12) ...... agonists in human whole blood
@nl
P1433
P1476
Effects of P2Y(1) and P2Y(12) ...... agonists in human whole blood
@en
P2093
Heptinstall S
P304
P356
10.1080/09537100120085450
P407
P577
2001-11-01T00:00:00Z